Drug Profile
Semaxanib - Pfizer
Alternative Names: Semoxind; SU 5416Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Cancer metastases; Colorectal cancer; Kaposi's sarcoma; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 08 Feb 2002 Discontinued - Phase-I for Cancer metastases in USA (IV)
- 08 Feb 2002 Discontinued - Phase-I for Solid tumours in Switzerland (PO)
- 08 Feb 2002 Discontinued - Phase-I for Solid tumours in USA (IV)